Pharvaris N.V.
Business
Pharvaris N.V. is a late-stage biopharmaceutical company developing innovative therapies for rare bradykinin-mediated angioedema diseases, primarily hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency. Its lead candidate, deucrictibant, is a novel oral small-molecule bradykinin B2 receptor antagonist in two formulations: an immediate-release capsule for on-demand treatment of acute attacks and an extended-release tablet for prophylactic prevention. The company is conducting pivotal Phase 3 clinical trials globally for both formulations and additional indications.
Summary from 20-F filed 2026-04-02
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-175.70M |
| Total assets | $301.45M |
| Total liabilities | $30.18M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Pharvaris N.V.'s CIK number?
Pharvaris N.V.'s SEC CIK number is 0001830487 (1830487). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Pharvaris N.V.'s SEC filings?
All of Pharvaris N.V.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.